Scott E. Lazerwith
53Patents
11h-index
133Co-inventors
77Inventor score
Filing activity: Oct 18, 2007 → Jun 14, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8088368B2 | Antiviral compounds | Chemistry; Metallurgy | 57 | Active |
| US9216996B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | Chemistry; Metallurgy | 43 | Active |
| US8273341B2 | Antiviral compounds | Chemistry; Metallurgy | 33 | Active |
| US9951043B2 | Therapeutic compounds | Chemistry; Metallurgy | 27 | Active |
| US8884030B2 | Inhibitors of Flaviviridae viruses | Emerging Cross-Sectional Technologies | 21 | Active |
| US8524764B2 | Inhibitors of Flaviviridae viruses | Emerging Cross-Sectional Technologies | 20 | Active |
| US9522912B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | Chemistry; Metallurgy | 19 | Active |
| US8575118B2 | Antiviral compounds | Chemistry; Metallurgy | 16 | Active |
| US9682084B2 | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide | Emerging Cross-Sectional Technologies | 16 | Active |
| US9376441B2 | Substituted pyrrolidines as SYK inhibitors | Chemistry; Metallurgy | 13 | Active |
| US8536187B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | Human Necessities | 11 | Active |
| US8841278B2 | Antiviral compounds | Chemistry; Metallurgy | 11 | Active |
| US10703733B2 | MCL-1 inhibitors | Human Necessities | 10 | Active |
| US9663528B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | Chemistry; Metallurgy | 10 | Active |
| US9732092B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | Chemistry; Metallurgy | 10 | Active |
| US10035809B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | Chemistry; Metallurgy | 9 | Active |
| US10988451B2 | MCL-1 inhibitors | Human Necessities | 9 | Active |
| US8822430B2 | Antiviral compounds | Chemistry; Metallurgy | 8 | Active |
| US9630978B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | Chemistry; Metallurgy | 8 | Active |
| US10098886B2 | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide | Emerging Cross-Sectional Technologies | 7 | Active |
| US11680064B2 | Capsid inhibitors for the treatment of HIV | Chemistry; Metallurgy | 7 | Active |
| US9511056B2 | Antiviral compounds | Chemistry; Metallurgy | 6 | Active |
| US8513298B2 | Inhibitors of flaviviridae viruses | Emerging Cross-Sectional Technologies | 5 | Active |
| US10005774B2 | Syk inhibitors | Chemistry; Metallurgy | 4 | Active |
| US10836769B2 | Substituted pyrrolizine compounds and uses thereof | Human Necessities | 4 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.